If you're new here, you may want to subscribe to my RSS feed. Thanks for visiting!

Boston Scientific Corporation (NYSE: BSX) has been down and almost out for almost as long as memory serves.  The company can’t even blame a bear market for its share price woes.  But the company has some solid news in its cardiac resynchronization therapy defibrillators showing a great reduction in death.  If this holds up, it could be one of the best things for the company in recent periods.

The company and the University of Rochester Medical Center have announced that the landmark MADIT-CRT trial has met its primary endpoint, where the preliminary results showed the cardiac resynchronization therapy defibrillators with a significant 29% reduction in death or heart failure interventions when compared to traditional implantable cardioverter defibrillators.

Read the full story »